

To decrease the risk of acquiring potentially serious vaccine-preventable diseases, Alaskans are recommended to stay up-to-date with all Advisory Committee on Immunization Practices (ACIP)-recommended vaccines.

Methods: VacTrAK data is assessed quarterly to examine vaccination coverage rates among Alaskans during the second quarter of 2023 (ending June 30, 2023). Vaccines were selected based on commonly used metrics for vaccine compliance as recommended by the ACIP.

Figure 1: Vaccine series coverage rate (%), 2018-2023 Q2

Following a decline during the COVID-19 pandemic, childhood vaccination coverage rates increased by 4% over the first two quarters of 2023. Kindergarten, adolescent, and adult vaccinations have been consistent within 1 percentage point the past year.




Figure 2: Vaccine series coverage rate (%) by Alaska region, 2023 Q2

Rates vary regionally and by age group; while childhood rates have improved, adolescent and adult rates remain stagnant. Public messaging and health care provider engagement can help raise coverage rates.




Table 1: Vaccine coverage rate (%) by region and vaccine

Regional differences may vary by age group and vaccine. There are consistently low rates for HPV vaccine among adolescents and zoster vaccine for adults ages 50 and older across all regions.

| | Anc | Gulf Coast | Interior | Mat-Su | Northern | Southeast | Southwest | 2023 Q1 | 2023 Q2 | 2022 |
|---------------------------------------|------------|-------------------|-----------------|---------------|-----------------|------------------|------------------|----------------|----------------|-------------|
| Childhood Series, 19-35 Months | 62 | 56 | 56 | 58 | 57 | 62 | 53 | 57 | 59 | 55 |
| 4 DTaP/DT/Td | 65 | 60 | 58 | 64 | 61 | 66 | 57 | 61 | 63 | 59 |
| 3 HIB | 78 | 73 | 71 | 77 | 83 | 79 | 83 | 75 | 77 | 73 |
| 3 Polio | 80 | 79 | 75 | 78 | 81 | 84 | 81 | 77 | 79 | 76 |
| 3 HepB | 84 | 82 | 80 | 81 | 90 | 87 | 89 | 82 | 84 | 80 |
| 1 MMR | 79 | 73 | 72 | 74 | 82 | 80 | 82 | 75 | 77 | 73 |
| 1 Varicella | 74 | 71 | 71 | 70 | 79 | 78 | 77 | 71 | 73 | 69 |
| 4 PCV | 76 | 71 | 70 | 72 | 79 | 77 | 77 | 72 | 74 | 71 |
| Kindergarten Series, 5-6 years | 64 | 56 | 53 | 56 | 80 | 59 | 67 | 61 | 61 | 62 |
| 5 DTaP/DT/Td UTD | 68 | 62 | 57 | 62 | 83 | 64 | 79 | 67 | 65 | 68 |
| 3 HepB | 89 | 89 | 83 | 84 | 96 | 90 | 96 | 88 | 88 | 88 |
| 2 MMR | 70 | 63 | 58 | 63 | 86 | 65 | 77 | 68 | 67 | 69 |
| 3 Polio | 88 | 88 | 82 | 84 | 96 | 90 | 95 | 88 | 88 | 88 |
| 2 Varicella | 68 | 61 | 57 | 61 | 84 | 63 | 71 | 66 | 65 | 66 |
| 2 Hep A | 78 | 76 | 69 | 75 | 92 | 81 | 89 | 78 | 77 | 78 |
| Adolescent Series, 13-17 Years | 37 | 22 | 26 | 27 | 56 | 36 | 61 | 36 | 35 | 36 |
| ≥1 Tdap/Td | 66 | 60 | 55 | 63 | 85 | 69 | 86 | 67 | 66 | 67 |
| ≥2 HPV | 38 | 23 | 27 | 28 | 60 | 38 | 62 | 37 | 36 | 37 |
| ≥1 MenACWY | 57 | 45 | 46 | 48 | 80 | 60 | 82 | 57 | 56 | 57 |
| Adults, 18 Years and Older | Anc | Gulf Coast | Interior | Mat-Su | Northern | Southeast | Southwest | 2023 Q1 | 2023 Q2 | 2022 |
| ≥1 Tdap (18+) | 59 | 56 | 58 | 50 | 79 | 68 | 70 | 60 | 60 | 60 |
| ≥1 Pneumo (65+) | 61 | 64 | 61 | 51 | 67 | 64 | 62 | 61 | 60 | 61 |
| ≥1 Zoster (50+) | 40 | 33 | 40 | 29 | 42 | 44 | 36 | 38 | 38 | 37 |

Childhood Series: 4 DTaP/DT/Td, 3 HIB, 3 Polio, 3 Hep B, 1 MMR, 1 Varicella, 4 PCV doses

Kindergarten Series: 5 DTaP/DT/Td, 3 Polio, 3 Hep-B, 2 MMR, 2 Varicella, 2 Hep A

Adolescent Series: 1 Tdap, 2 HPV, 1 MenACWY